Artesunate Injection I.P. (Malrisa-RT 120 mg)
Overview Service
Malrisa-RT contains Artesunate, a water-soluble hemisuccinate derivative of artemisinin, used primarily for the treatment of severe malaria. It acts quickly against malaria parasites in the blood, especially Plasmodium falciparum.
- Fast-acting antimalarial injection
- Administered intramuscularly or intravenously
- Effective against drug-resistant strains
- Supplied as a single-dose vial with accompanying solvent
- WHO-recommended treatment for severe malaria
Uses / Indications
- Primary Use: Treatment of severe malaria, particularly caused by Plasmodium falciparum
- Also used in chloroquine-resistant malaria cases
- Sometimes employed in combination with other antimalarials for complete parasite clearance
Dosage & Administration
- Route: Intravenous (IV) or Intramuscular (IM)
- Initial dose: 2.4 mg/kg body weight IV or IM
- Follow-up dose: At 12 hours and 24 hours after the initial dose, then once daily for up to 7 days or until oral medication can be administered
- Should be administered by a healthcare professional
Precautions
- Do not self-administer; to be used under medical supervision only
- Caution in patients with liver or kidney disorders
- Monitor for delayed hemolytic anemia after treatment
- Not recommended during the first trimester of pregnancy unless no alternatives are available
- May cause dizziness; avoid driving or operating machinery
- Allergic reactions or hypersensitivity to Artesunate or derivatives should be considered
